Alanazi, F.E.; Alatawi, Y.; Alattar, A.; Alshaman, R.; Kotb, A.A.; Hetta, H.F.
Broad-Spectrum RAS Inhibition in Pancreatic Ductal Adenocarcinoma: Mechanistic Advances and Therapeutic Promise. Pharmaceuticals 2025, 18, 1788.
https://doi.org/10.3390/ph18121788
AMA Style
Alanazi FE, Alatawi Y, Alattar A, Alshaman R, Kotb AA, Hetta HF.
Broad-Spectrum RAS Inhibition in Pancreatic Ductal Adenocarcinoma: Mechanistic Advances and Therapeutic Promise. Pharmaceuticals. 2025; 18(12):1788.
https://doi.org/10.3390/ph18121788
Chicago/Turabian Style
Alanazi, Fawaz E., Yasser Alatawi, Abdullah Alattar, Reem Alshaman, Ahmed A. Kotb, and Helal F. Hetta.
2025. "Broad-Spectrum RAS Inhibition in Pancreatic Ductal Adenocarcinoma: Mechanistic Advances and Therapeutic Promise" Pharmaceuticals 18, no. 12: 1788.
https://doi.org/10.3390/ph18121788
APA Style
Alanazi, F. E., Alatawi, Y., Alattar, A., Alshaman, R., Kotb, A. A., & Hetta, H. F.
(2025). Broad-Spectrum RAS Inhibition in Pancreatic Ductal Adenocarcinoma: Mechanistic Advances and Therapeutic Promise. Pharmaceuticals, 18(12), 1788.
https://doi.org/10.3390/ph18121788